Data Readout

Vaxart's Oral COVID Vaccine Faces First Efficacy Test Against mRNA Shot in 2027

The Phase 2b readout will be the first data on whether Vaxart's oral pill vaccine can beat a commercial mRNA booster on infection prevention, a bar the AppliedXL model puts at 49.4%.

By AppliedXLJuly 13, 2026Trial NCT06672055

Executive Summary

Vaxart expects the primary efficacy and safety data from the roughly 5,000-participant KP.2 main cohort of its Phase 2b trial in early 2027, the first controlled comparison of its oral pill vaccine against a commercial mRNA booster. This determines whether the oral platform can show a measurable infection-prevention effect against an approved comparator.
The trial has been rated Unstable by AppliedXL's protocol stability tool, with enrollment revised three times, from 10,000 down to 400, back up to 10,400, then down to 5,485, and the primary completion date pushed 16 months. This pattern lowers confidence that the stated H1-2027 window will hold without further slippage.
AppliedXL's Probability of Success sits at 49.4% on the endpoint-met basis, carrying a LOW confidence label and a wide uncertainty band. The read is weighed down by weak historical success rates for this endpoint type, and the confidence level itself signals the model has limited grip on this specific outcome.
The registry lists seven primary endpoints without a disclosed hierarchy or statistical bar, so it is not yet possible to say what magnitude of effect on symptomatic PCR-positive infection would count as a positive result. This is the single largest gap standing between the current data and an informed thesis.
The readout is not registrational, so even a positive signal establishes hypothesis support rather than a regulatory pathway; the real test is whether the result gives Vaxart grounds to design a Phase 3 program.

The catalyst

Vaxart says it expects the primary efficacy and safety readout from the roughly 5,000-participant KP.2 main cohort of its Phase 2b trial in early 2027 Press Release. Steven Lo, Chief Executive Officer of Vaxart, said the company is "dedicating resources to manage the 5,000-participant main study cohort, which is a primary focus of our clinical efforts," and that the company anticipates "the primary efficacy and safety data readout from this larger group in early 2027" Press Release. The trial, NCT06672055, is a randomized, active-comparator Phase 2 study testing the oral pill vaccine against a commercially available mRNA injectable booster NCT06672055. The stated window runs 2027-01-01 to 2027-06-30, still open as of the current date.

Probability of Success

Endpoint Met49%

Completes95%

Clinical Significance50%

Regulatory94%

What the trial can show

The registry lists seven primary endpoints, split between the earlier XBB sentinel safety cohort and the KP.2 main cohort's measures of symptomatic PCR-positive COVID-19 at 14 days and at 12 months post-vaccination NCT06672055. Twenty-three secondary endpoints track antibody and T-cell responses across multiple timepoints NCT06672055. The design uses an active comparator, a commercially available mRNA vaccine identified in trial records as COMIRNATY, rather than placebo NCT06672055. The study is explicitly non-registrational, so even a favorable infection-rate result would support further development planning rather than a direct regulatory filing.

Protocol history

The trial's operational record shows repeated revision. Enrollment moved from 10,000 to 400 in April 2025, back up to 10,400 in June 2025, then down to 5,485 in June 2026, a net decline of 45.1% from the 10,400 peak. The primary completion date shifted from 2026-01-01 to 2026-11-01 in June 2025, then to 2027-05-01 in June 2026, a cumulative slip of 16 months. AppliedXL's protocol stability tool labels the trial Unstable, citing 5 total change events at a rate of 4.2 per year. Vaxart's sponsor profile shows a 94.4% overall trial completion rate across 36 prior studies, indicating the volatility here is unusual relative to the company's broader track record.

The competitive picture

No other trial in the AppliedXL landscape combines an oral vaccine against the SARS-CoV-2 Spike Protein target with a head-to-head comparison against a commercial mRNA booster; the nearest same-target program is a 20-participant Phase 1 study from Rokote Laboratories Finland Oy, not a direct comparator in scale or design. Overall field activity in this target has declined, with 23 recent trials against 267 older ones, a ratio AppliedXL flags as accelerating field decline. That combination, an isolated design and a cooling field, means a positive result would carry weight mainly as a first data point for the oral vaccine platform rather than a signal read against an active peer group.

The model read

AppliedXL's Probability of Success for the endpoint-met outcome stands at 49.4%, carrying a LOW confidence label and a wide uncertainty band [AXL-MODEL]. The read rests heavily on operational design and endpoint-history features, including the endpoint-type success rate, the phase endpoint success rate, and enrollment per arm, rather than on mechanism-specific evidence [AXL-MODEL]. That mix means the number reflects statistical base rates for this endpoint type and phase more than a judgment about the vaccine's biology, a reason to treat it as a rough guide rather than a precise forecast.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.